Federal Register Notice: FDA is reopening until 5/30, the comment period for three concept papers entitled “Premarketing Risk Assessment,” “Risk Management Programs,” and “Risk Assessment of Observational Data: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment.” To view this notice, click here.
